Viatris Takes Strategic Step by Selling Stake in Biocon Biologics Limited Viatris Inc. has finalized agreements with Biocon Limited to sell its stake in Biocon Biologics. This strategic move is set to redefine their market position and growth opportunities.

Viatris Takes Strategic Step by Selling Stake in Biocon Biologics Limited #None #healthcare #Biocon_Biologics #Viatris

Biocon Biologics and Civica Expand Insulin Glargine Supply for U.S. Diabetes Patients Biocon Biologics partners with Civica to enhance U.S. diabetes treatment through private-label Insulin Glargine, improving patient access to affordable medication.

Biocon Biologics and Civica Expand Insulin Glargine Supply for U.S. Diabetes Patients #None #Civica #Biocon_Biologics #Insulin_Glargine

Biocon Biologics Set to Launch Denosumab Biosimilars in the U.S. Market Biocon Biologics has secured entry into the U.S. market for their denosumab biosimilars, Bosaya™ and Aukelso™, enhancing treatment options for osteoporosis and cancer-related bone conditions.

Biocon Biologics Set to Launch Denosumab Biosimilars in the U.S. Market #United_States #Bridgewater #Biocon_Biologics #Bosaya #Aukelso

Biocon Biologics Celebrates FDA Approval of Two Critical Biosimilars, Bosaya™ and Aukelso™ Biocon Biologics has received FDA approval for its new biosimilars, Bosaya™ and Aukelso™, aimed at enhancing access to vital therapies for osteoporosis and oncology.

Biocon Biologics Celebrates FDA Approval of Two Critical Biosimilars, Bosaya™ and Aukelso™ #India #Bengaluru #Biocon_Biologics #Bosaya #Aukelso

European Commission Grants Approval for Biocon Biologics' New Denosumab Biosimilars to Enhance Bone Health The European Commission has authorized Biocon Biologics' Denosumab biosimilars, Vevzuo and Evfraxy, for improved bone health in cancer and osteoporosis patients.

European Commission Grants Approval for Biocon Biologics' New Denosumab Biosimilars to Enhance Bone Health #None #Denosumab #Biocon_Biologics #Vevzuo

European Commission Approves Biocon Biologics' Denosumab Biosimilars for Bone Health Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo® and Evfraxy®, enhancing bone health treatments in Europe.

European Commission Approves Biocon Biologics' Denosumab Biosimilars for Bone Health #India #Bangalore #Denosumab #Biocon_Biologics #Osteoporosis

European Commission Approves Biocon's Denosumab Biosimilars for Bone Health Biocon Biologics announces successful approval of Denosumab biosimilars Vevzuo and Evfraxy by the European Commission to enhance bone health treatment access.

European Commission Approves Biocon's Denosumab Biosimilars for Bone Health #India #Bengaluru #Denosumab #Biosimilars #Biocon_Biologics

European Commission Grants Approval for Biocon Biologics’ Denosumab Biosimilars, Vevzuo and Evfraxy Biocon Biologics Ltd has received European Commission approval for its biosimilars, Vevzuo® and Evfraxy®, aimed at improving bone health and treating osteoporosis.

European Commission Grants Approval for Biocon Biologics’ Denosumab Biosimilars, Vevzuo and Evfraxy #India #Bengaluru #Denosumab #Biocon_Biologics #Vevzuo

Biocon Biologics Gains Favorable CHMP Opinions for Denosumab Biosimilars in Europe Biocon Biologics has received positive recommendations from CHMP for its denosumab biosimilars aimed at bone health, paving the way for new treatment options.

Biocon Biologics Gains Favorable CHMP Opinions for Denosumab Biosimilars in Europe #India #Bengaluru #Denosumab #Biocon_Biologics #Vevzuo

Biocon Biologics Secures Positive CHMP Opinions for Denosumab Biosimilar in Europe Biocon Biologics Ltd has received encouraging recommendations from the CHMP for its Denosumab biosimilar aimed at improving bone health in Europe.

Biocon Biologics Secures Positive CHMP Opinions for Denosumab Biosimilar in Europe #India #Bengaluru #Denosumab #Biocon_Biologics #Vevzuo

Positive CHMP Opinions Boost Biocon Biologics’ Biosimilar Denosumab for Bone Health in Europe Biocon Biologics has received favorable reviews from the CHMP for its Denosumab biosimilars targeting bone health, marking a significant milestone.

Positive CHMP Opinions Boost Biocon Biologics’ Biosimilar Denosumab for Bone Health in Europe #India #Bengaluru #Denosumab #Biosimilars #Biocon_Biologics

Biocon Biologics Paves the Way for Yesafili™ Launch in U.S. Market as an Interchangeable Biosimilar Biocon Biologics announces a significant settlement agreement, allowing Yesafili™, a biosimilar to Eylea®, to enter the U.S. market.

Biocon Biologics Paves the Way for Yesafili™ Launch in U.S. Market as an Interchangeable Biosimilar #United_States #Eylea #Bridgewater #Biocon_Biologics #Yesafili

Biocon Biologics Secures FDA Approval for Jobevne™, Enhancing Cancer Treatment Options Biocon Biologics has announced U.S. FDA approval for Jobevne™, a crucial addition to its oncology portfolio, expanding treatment options for cancer. This biosimilar to Avastin is significant for improving patient access.

Biocon Biologics Secures FDA Approval for Jobevne™, Enhancing Cancer Treatment Options #United_States #Bridgewater #Biocon_Biologics #Avastin #Jobevne

Biocon Biologics Introduces YESINTEK™: A New Biosimilar to Stelara® in the U.S. Biocon Biologics has launched YESINTEK™ in the United States, a promising biosimilar to Stelara® aimed at chronic autoimmune diseases, increasing patient accessibility to healthcare.

Biocon Biologics Introduces YESINTEK™: A New Biosimilar to Stelara® in the U.S. #United_States #Biocon_Biologics #YESINTEK™ #Stelara® #Bridgewater,_N.J.

Biocon Biologics Set to Showcase Innovations at J.P. Morgan Healthcare Conference 2025 Biocon Biologics will present its commitment to accessible healthcare at the 43rd Annual J.P. Morgan Healthcare Conference, showcasing their innovative biosimilars.

Biocon Biologics Set to Showcase Innovations at J.P. Morgan Healthcare Conference 2025 #India #Bengaluru #Healthcare_Access #Biosimilars #Biocon_Biologics